Comparative Pharmacology
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVORA 0 15 30 21 versus PHILITH.
LEVORA 0.15/30-21 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; levonorgestrel inhibits ovulation and thickens cervical mucus, impairing sperm penetration. Also induces endometrial atrophy.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet orally once daily for 21 days, followed by 7 tablet-free days.
1 mg orally once daily
None Documented
None Documented
20-30 hours for ethinyl estradiol; 2-4 hours for levonorgestrel. Steady-state reached in 5-7 days
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Urine (50-60% as metabolites), feces (30-40% as glucuronides); <10% unchanged
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive